Chlamydiazyme is a 4-h enzyme-linked immunoassay that detects an antigen of Chiamydia trachomatis directly in clinical specimens. This immunoassay was compared with cell culture for the diagnosis of chlamydial infections of the genital tract. The assay was evaluated at five clinics with a total of 1,277 cervical specimens of which 239 were culture positive. At three of these clinics where urethral samples were taken from males, 99 of 363 samples were culture positive. The sensitivity of the assay averaged 89.5% for detecting cervical infections and 78.8% for detecting male urethral infections. Specificity was 97.0% when samples from either males or females were tested. Some patients who were culture negative were infected with chlamydiae according to both Chlamydiazyme and a monoclonal antibody test that detected a chlamydial antigen distinct from the antigen detected by Chlamydiazyme. If the 15 females and 2 males who were positive by both immunoassays but culture negative were considered positive for chlamydial infection, the specificity of the assay was 98.4% in females and 97.7% in males. Chlamydiazyme is a simple and relatively rapid immunoassay that has sufficient sensitivity and specificity to supplant culture in the detection of genital chlamydial infections.
The treatment and control of genital chlamydial infections has been hampered by the lack of a diagnostic test that is rapid and suitable for routine use in the clinical microbiology laboratory. The standard method for diagnosis is the propagation of chlamydiae in cultured mammalian cells and the subsequent staining of inclusions. Specificity is near 100% when experienced microscopists examine the cultures. Sensitivity, which is influenced by sampling procedures, cultural conditions, and staining methodology, probably varies between 70 and 90% (9) .
Deficiencies in culture include loss of viability due to either toxic swabs (4) or storage of specimens before culture is performed. In addition, identification by culture requires 2 or 4 to 6 days if a second passage is used to increase sensitivity. The expense of culture and the need for experienced personnel further detract from this method as a routine diagnostic procedure.
Commerical assays, which serve as an alternative to culture, include a direct immunofluorescent antibody (IFA) test (13) and enzyme-linked immunoassays (EIAs) (3) . In this paper, we describe the performance of Chlamydiazyme, which is a 4-h immunoassay that detects a chlamydial antigen directly in clinical samples. The performance of Chlamydiazyme during early stages of development was previously reported (1, 6) . The data reported here were obtained at five clinical locations by using the Chlamydiazyme reagents that are now commerically available from Abbott Laboratories.
MATERIALS AND METHODS
Specimens. Chlamydiazyme was evaluated at five clinical sites with samples from female patients. At three of these clinics, specimens from males were also tested. Written informed consent was obtained from each patient before samples were taken. The population studied and the incidence of Chlamydia trachomatis infection for each site are presented in Table 1 . Separate swabs were used for the culture of chlamydiae and for antigen detection by immunoassay. The exocervix was cleared of mucus with a cotton swab before samples were taken. Specimens for the culture of chlamydiae from females were taken with a cotton (sites I, II, IV, V) or dacron (site III) swab which was rotated in the cervical os for 15 to 30 s. The male urethral specimen for culture was taken with a cotton swab, except at site III where a dacron swab was used. Swabs for Chlamydiazyme were supplied with the kits and were used to obtain specimens from the same anatomical sites sampled for culture.
IFA and culture. At sites III and IV, the Syva MicroTrak direct IFA test (13) was run concurrently with Chlamydiazyme and cell culture. For the direct IFA test, a separate swab was taken to prepare a smear on a glass slide (site IV), or the smear was made from the swab for culture before it was placed in sucrose-phosphate transport medium (2-SP) (4) (site III). Swabs used for culture were placed in 2-SP or Eagle minimum essential medium and tested within 8 h or frozen. No samples stored in minimum essential medium were frozen. One-tenth of the swab eluate was placed on each of duplicate McCoy cell monolayers. McCoy cell cultures for inoculation were grown on cover slips in glass vials in all laboratories, except at site IV where microtiter trays (15) were used. The inoculated cells were centrifuged at 2,000 to 2,500 x g at 35°C for 30 min. Cell culture medium was supplemented with cycloheximide. After 48 to 72 h of incubation at 35°C, one of the duplicate monolayers was stained with iodine (passage 1). At site I, an additional passage 1 monolayer was stained with IFA monoclonal antibody (11) . At all sites, passage 2 was performed by scraping cells off the duplicate cover slip and inoculating monolayers with this suspension. These cultures were centrifuged, incubated, and stained with iodine as described for passage 1. Culture was considered positive if passage 1 or 2 monolayers contained one or more chlamydial inclusions.
Chlamydiazyme procedure. The swab for Chlamydiazyme was placed in a transport tube containing 0.1 ml of storage reagent and was tested within 72 h after sample collection. Specimen dilution buffer (1 ml) was added to elute chlamyd- Thus, direct IFA on specimens at two sites and examination of 14 2-SP and 10 specimen dilution buffer samples by IFA indicated that 2 males and 15 females who were culture negative probably were infected with chlamydiae. If these 17 patients were infected, the resolved specificity of Chlamydiazyme was 97.7 and 98.4% for males and females, respectively (Table 3 ).
DISCUSSION
The standard method for diagnosis of genital chlamydial infections is isolation with cultured mammalian cells. Several researchers (9, 15) (7) . In addition, a rise in antibody titer or seroconversions in some culture-negative males with nongonococcal urethritis indicated that culture is not 100% sensitive in detecting male urethral infections (5, 14) . Schachter (9) Resolution of some false-positive results was achieved at two sites where direct examination of specimens by fluorescent monoclonal antibody was performed. These results, in addition to the observation of chlamydiae in 2-SP and specimen dilution buffer samples, increased the specificity from 97.0 to 98.4% in females. Specificity in males increased from 97.0 to 97.7%. The monoclonal antibody used to resolve these discordant results reacts with the major outer membrane protein (12, 13) . The antiserum used in Chlamydiazyme has been purified and reacts only with the chlamydial lipopolysaccharide (unpublished data). Reactivity with chlamydial lipopolysaccharide but not the major outer membrane protein was demonstrated by electrophoresis of solubilized chlamydiae and subsequent immunoblotting by a published procedure (2) . It is unlikely that antigens crossreacting with both the antichlamydial major outer membrane protein and lipopolysaccharide antibodies would be present simultaneously in chlamydiae-negative specimens.
Early detection and treatment of chlamydial infections in women, many of whom are asymptomatic, would decrease the incidence of serious complications, which include endometritis, salpingitis, and perihepatitis (10) . In addition, the test would be useful in the detection of chlamydial infections in pregnant women whose infants are at high risk for inclusion conjunctivitis and pneumonitis (8) . In males, chlamydial urethritis, which is largely indistinguishable from gonococcal urethritis on the basis of symptoms, could be correctly diagnosed. Correct diagnosis would be particularly important in the management of males with concurrent gonococcal and chlamydial infections, of which many would be treated on the basis of a Gram stain with an antibiotic that is appropriate only for gonorrhea.
In summary, Chlamydiazyme fulfills a need for a routine diagnostic test for the identification of patients with genital chlamydial infections. The correct diagnosis and treatment of patients will be an important adjunct to public health programs designed to prevent infections caused by C. trachomatis.
